Evotec (ETR:EVT) Shares Pass Below 50 Day Moving Average – Time to Sell?

Evotec SE (ETR:EVT)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of €4.46 and traded as low as €3.45. Evotec shares last traded at €3.45, with a volume of 754,876 shares.

Evotec Stock Performance

The company’s fifty day simple moving average is €4.46 and its 200 day simple moving average is €5.01. The company has a current ratio of 1.68, a quick ratio of 2.97 and a debt-to-equity ratio of 55.38. The stock has a market capitalization of $636.42 million, a P/E ratio of -3.71, a P/E/G ratio of 0.98 and a beta of 1.31.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.